- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments
A panelist discusses how HIV treatment has evolved with tremendous improvements in efficacy, tolerability, and convenience, with exciting developments at the Conference on Retroviruses and Opportunistic Infections 2025, including new long-acting therapies for treatment and prevention that could last up to 2 years.
EP: 1.HIV Viral Suppression: Clinical Significance and Impact on Patient Outcomes
EP: 2.Changing Patient Demographics in HIV and Impacts of Polypharmacy on Treatment
EP: 3.Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials
EP: 4.HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations
EP: 5.Long-Acting HIV Therapies: Real-World Data and Clinical Application
EP: 6.CD4 T-cell and Lymphocyte Monitoring: Clinical Significance in HIV Treatment
EP: 7.CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments
Future Directions in HIV Treatment
Key Themes:
- Treatment Evolution: Continuous improvement in HIV medications regarding efficacy, tolerability, and convenience
- Long-Acting Formulations: Development of oral, subcutaneous, intramuscular, and intravenous options
- Combination Products: Future devices potentially combining HIV treatment/prevention with contraception or sexually transmitted infection prevention
- HIV Prevention: New preventive therapies potentially effective for 1 to 2 years
Notable Insights from Dr Sharon Walmsley:
- Long-acting therapies help “demedicalize” HIV by reducing medication frequency.
- New challenges in adherence emerge with transition from daily to weekly or monthly dosing schedules.
- HIV treatment advances have informed approaches to other infectious diseases, including COVID-19 and Mpox.
- Despite prevention advances, questions remain about whether to continue vaccine development efforts given limited success to date.
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds
August 5th 2025Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.
Read More
